Trending >

ProMetic Life Sciences’s Phase II MetS Data keeps getting better, says Paradigm

ProMetic Life Sciences

ProMeticThe results from ProMetic Life Science’s (ProMetic Life Sciences Stock Quote, Chart, News: TSXV:PLI) ongoing Phase II trial have been outstanding, says Paradigm Capital analyst Christopher Lam.

This morning, ProMetic released data on an additional nine patients that are enrolled in its BI-4050 phase 2 open-label study in patients suffering from type 2 diabetes and metabolic syndrome. The company said the results confirm the pharmacological activity from the first 11 patients, including a decrease in HbA1c.

“PBI-4050’s reduction of HbA1c in our open-label trial is a very strong efficacy signal that provides us with very valuable insight for the placebo controlled clinical trial design in patients with chronic kidney disease with diabetes and in patients with metabolic syndrome and diabetes,” said CEO Pierre Laurin. “We are very confident about the prospect of PBI-4050’s clinical performance in the other ongoing clinical trials and the placebo-controlled studies we are initiating.”

Lam says the results should bode well for future trials.

“The key take-away is that the three sets of results from this Phase II trial have been outstanding,” says Lam. “The data suggests a clear and significant efficacy signal that indicates the potential effects of PBI-4050 in improving blood glucose control and inflammation in patients with diabetes (and without side effects). This should provide investors with increased confidence ahead of the planned pivotal study in patients with chronic kidney disease and diabetes, and the other Phase II trials where diabetes is involved.

In a research update to clients today, Lam maintained his “Buy” rating and one-year price target of $5.50 on ProMetic Life Sciences, implying a return of 60 per cent at the time of publication, including dividend.

More Cantech Life Sciences

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
insta twitter facebook


Leave a Reply